{"id":30668,"date":"2024-12-27T17:20:00","date_gmt":"2024-12-27T11:50:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30668"},"modified":"2024-12-24T15:21:00","modified_gmt":"2024-12-24T09:51:00","slug":"gene-therapy-for-sickle-cell-disease-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment","title":{"rendered":"Sickle Cell Disease Treatment: How Gene Therapy and Editing Could Transform Therapeutic Segment?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69ff3264424c7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69ff3264424c7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment\/#CASGEVY_and_LYFGENIA_%E2%80%94_Market_Leaders_in_Sickle_Cell_Disease_Treatment\" >CASGEVY and LYFGENIA \u2014 Market Leaders in Sickle Cell Disease Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment\/#Potential_Sickle_Cell_Disease_Therapies_on_the_Horizon\" >Potential Sickle Cell Disease Therapies on the Horizon<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment\/#The_European_Hematology_Association_EHA_2024_Hybrid_Congress_Key_Highlights\" >The European Hematology Association (EHA) 2024 Hybrid Congress: Key Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment\/#Key_Developments_in_Sickle_Cell_Disease_Treatment_Space\" >Key Developments in Sickle Cell Disease Treatment Space<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment\/#Sickle_Cell_Disease_Treatment_What_Lies_Ahead\" >Sickle Cell Disease Treatment: What Lies Ahead?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Sickle cell disease is a hereditary blood disorder marked by abnormal hemoglobin, which leads to the deformation of red blood cells into a sickle shape. It is a major global health issue, especially common in individuals of African, Middle Eastern, Mediterranean, and South Asian descent.<\/p>\n\n\n\n<p>Based on DelveInsight&#8217;s assessment in 2023, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-6mm-epidemiology-forecast\">total prevalent cases of SCD<\/a> in the 6MM were nearly&nbsp; <strong>177K<\/strong>. These cases are expected to increase by 2034. As per the estimates, the US accounted for approximately <strong>54%<\/strong> of the total prevalent cases of SCD trait in the 6MM.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Sickle cell disease poses significant challenges for affected individuals, impacting their quality of life and life expectancy. Common complications include anemia, acute chest syndrome, stroke, organ damage (e.g., kidneys, liver), and increased susceptibility to infections.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-casgevy-and-lyfgenia-market-leaders-in-sickle-cell-disease-treatment\"><span class=\"ez-toc-section\" id=\"CASGEVY_and_LYFGENIA_%E2%80%94_Market_Leaders_in_Sickle_Cell_Disease_Treatment\"><\/span><strong>CASGEVY and LYFGENIA \u2014 Market Leaders in Sickle Cell Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gene therapy and gene editing techniques hold promise in correcting the underlying genetic mutation responsible for SCD. In December 2023, the FDA approvals of two gene therapies, <strong>Vertex\/CRISPR\u2019s CASGEVY<\/strong>, and <strong>Bluebird\u2019s LYFGENIA<\/strong> offer the potential of a one-time transformative therapy for eligible patients with SCD.&nbsp;<\/p>\n\n\n\n<p>CASGEVY is a genome-edited cellular therapy made from autologous CD34+ hematopoietic stem cells (HSCs) that are modified using CRISPR\/Cas9 technology. The editing occurs at the erythroid-specific enhancer region of the BCL11A gene. It is designed for a one-time treatment through a hematopoietic stem cell transplant, where the patient&#8217;s own CD34+ cells are altered to reduce BCL11A expression in erythroid lineage cells. This modification boosts the production of fetal hemoglobin (HbF), the oxygen-carrying form of hemoglobin naturally present during fetal development, which transitions to adult hemoglobin after birth. CASGEVY has shown potential in reducing or eliminating vaso-occlusive crises in patients with sickle cell disease.<\/p>\n\n\n\n<p>In December 2023, Vertex Pharmaceuticals and CRISPR Therapeutics announced that the US FDA approved CASGEVY, a CRISPR\/Cas9-edited cell therapy, for treating sickle cell disease in patients aged 12 and older with recurrent vaso-occlusive crises (VOCs).<\/p>\n\n\n\n<p>Additionally, CASGEVY received conditional marketing authorization in Great Britain from the UK Medicines and Healthcare Products Regulatory Agency and in Bahrain from the National Health Regulatory Authority for patients 12 and older with sickle cell disease characterized by recurrent VOCs or transfusion-dependent beta-thalassemia (TDT). This approval applies to patients for whom hematopoietic stem cell transplantation is suitable but a human leukocyte antigen-matched related stem cell donor is unavailable.<\/p>\n\n\n\n<p>LYFGENIA is a one-time, ex-vivo lentiviral vector gene therapy approved for treating patients aged 12 and older with sickle cell disease and a history of vaso-occlusive events (VOEs). It works by introducing a functional \u03b2-globin gene into the patient\u2019s own hematopoietic stem cells (HSCs). Following successful engraftment, it allows for the durable production of adult hemoglobin with anti-sickling properties (HbAT87Q). HbAT87Q closely resembles wild-type HbA in oxygen-binding affinity, reduces red blood cell sickling, and has the potential to decrease VOEs.<\/p>\n\n\n\n<p><strong><em>Read our article \u201c<\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/lyfgenia-or-casgevy-for-sickle-cell-disease-treatment\"><strong><em>LYFGENIA or CASGEVY: Who Will Lead the Sickle Cell Disease Treatment Space?<\/em><\/strong><\/a><strong><em>\u201d and get a more detailed analysis<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-potential-sickle-cell-disease-therapies-on-the-horizon\"><span class=\"ez-toc-section\" id=\"Potential_Sickle_Cell_Disease_Therapies_on_the_Horizon\"><\/span><strong>Potential Sickle Cell Disease Therapies on the Horizon<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-pipeline-insight\">sickle cell disease pipeline<\/a> possesses some drugs in mid- and late-stage developments to be approved in the near future. The expected launch of therapies such as <strong>EDIT-301<\/strong> (Editas Medicine), <strong>Inclacumab <\/strong>(Pfizer), <strong>Motixafortide <\/strong>(BiolineRx), <strong>Etavopivat <\/strong>(Novo Nordisk), <strong>Mitapivat <\/strong>(Agios Pharmaceuticals), and others shall further create a positive impact on the sickle cell disease treatment market.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"532\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151957\/Emerging-Therapies-for-Sickle-Cell-Disease-1024x532.jpg\" alt=\"Emerging-Therapies-for-Sickle-Cell-Disease\" class=\"wp-image-30677\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151957\/Emerging-Therapies-for-Sickle-Cell-Disease-1024x532.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151957\/Emerging-Therapies-for-Sickle-Cell-Disease-300x156.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151957\/Emerging-Therapies-for-Sickle-Cell-Disease-150x78.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151957\/Emerging-Therapies-for-Sickle-Cell-Disease-768x399.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151957\/Emerging-Therapies-for-Sickle-Cell-Disease-1536x798.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151957\/Emerging-Therapies-for-Sickle-Cell-Disease-2048x1064.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Additionally, the emergence of several mechanisms of action like, erythrocyte pyruvate kinase activator, cytidine deaminase (CDA) inhibitor, fetal hemoglobin production stimulant, DNA-dependent RNA polymerase inhibitor, and others will be expanding the treatment landscape of SCD.<\/p>\n\n\n\n<p>Even though it is too soon to comment on the above-mentioned promising candidate to enter the market during the forecast period (2024\u20132034), it is safe to assume that the future of this market is bright. Eventually, the drug will create a significant difference in the landscape of sickle cell disease in the coming years. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-6mm-market\">sickle cell disease treatment space<\/a> is expected to experience a positive impact in the coming years owing to the improvement in the rise in the number of healthcare spending across the world.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-european-hematology-association-eha-2024-hybrid-congress-key-highlights\"><span class=\"ez-toc-section\" id=\"The_European_Hematology_Association_EHA_2024_Hybrid_Congress_Key_Highlights\"><\/span><strong>The European Hematology Association (EHA) 2024 Hybrid Congress: Key Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Below are the potential sickle cell disease data readouts held at the 2024 EHA Hybrid Congress:<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-da921809-7fff-5bb1-2afb-8d22776c5a3c\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"left\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"91\" \/><col width=\"98\" \/><col width=\"81\" \/><col width=\"119\" \/><col width=\"212\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Drug<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Company<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Abstract No.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Abstract Title<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Data Readouts<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Pociredir<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Fulcrum Therapeutics<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">S294<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Interim results of a Phase Ib study (PIONEER) of an oral HBF inducer, pociredir, in sickle cell disease<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; In 16 adults, 10 experienced 23 TEAEs at a rate of 63%, with 8 of these related to the study drug. All TEAEs were mild and non-serious.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; No deaths, or discontinuations occurred due to TEAEs.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; All adherent participants showed induced HbF levels, with increases up to 9.8% and 10.0% over baseline in the 6 mg and 12 mg cohorts, respectively.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; Pociredir exhibited dose-dependent HbF increases unaffected by hydroxyurea use.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; Improvements in hemolysis biomarkers.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Osivelotor<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Pfizer<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">S291<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Preliminary results from a multicenter Phase II\/III study of next-generation HBS polymerization inhibitor osivelotor (GBT021601) for the treatment of patients with sickle cell disease<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; At week 12, mean increases in Hb (g\/dL) were 2.63 for the 100-mg group and 3.27 for the 150-mg group.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; EImax increased from 0.37 to 0.53 in the 100-mg group and from 0.42 to 0.50 in the 150-mg group.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; PoS (mmHg) decreased from 37.8 to 20.8 and from 32.5 to 15.3 in the 100-mg and 150-mg groups, respectively.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; Treatment-emergent adverse events (TEAEs) were reported in 20 patients (57.1%).<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; Two patients discontinued treatment due to adverse events.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">EDIT-301<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Editas Medicine<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">S285<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 6pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Reni-cel, the first ASCAS12A gene-edited cell therapy, led to hemoglobin normalization and increased fetal hemoglobin in severe sickle cell disease patients in an interim analysis of the Phase I\/II\/III RUBY trial<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; At month 6, the mean (SD) total Hb was 14.3 g\/dL (2.1 g\/Dl) with a mean (SD) HbF of 48.5%.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; The mean percentage of F-cells increased early and were sustained at &gt;90% from Month 4.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; Improvement or normalization of hemolysis markers.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; Successful neutrophil and platelet engraftment.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Developments_in_Sickle_Cell_Disease_Treatment_Space\"><\/span><strong>Key Developments in Sickle Cell Disease Treatment Space<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>October 2024, Kind Pharmaceutical (Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC)<\/strong> announced that the FDA\u2019s Office of Orphan Products Development has granted <strong>Orphan Drug Designation (ODD)<\/strong> to <strong>AND017 <\/strong>for the treatment of Sickle Cell Disease<\/li>\n\n\n\n<li>In <strong>September 2024, Pfizer<\/strong> voluntarily withdrew all lots of <strong>OXBRYTA <\/strong>for the treatment of SCD in all markets where it was approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanding access programs worldwide.&nbsp;<\/li>\n\n\n\n<li>In <strong>March 2024, Pfizer<\/strong> discontinued one of its two Phase III studies evaluating the anti-P-selecting antibody <strong>inclacumab <\/strong>in sickle cell disease due to \u201cpoor accrual and associated recruitment challenges.\u201d<\/li>\n\n\n\n<li>In <strong>February 2024,<\/strong> the European Commission granted conditional marketing authorization to <strong>CASGEVY <\/strong>for the treatment of patients who are 12 years of age and older with severe sickle cell disease.<\/li>\n\n\n\n<li>In <strong>December 2023, Editas Medicine<\/strong> announced new safety and efficacy data of <strong>EDIT-301<\/strong> from the <strong>RUBY trial<\/strong> for severe SCD at the American Society of Hematology (ASH) annual meeting.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sickle_Cell_Disease_Treatment_What_Lies_Ahead\"><\/span><strong>Sickle Cell Disease Treatment: What Lies Ahead?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Currently, the treatment of sickle cell disease involves <strong>NSAIDs, blood transfusions, chelating agents, nutritional supplements, and broad-spectrum antibiotics<\/strong>. Additionally, the US FDA has approved specific therapies for managing the condition, including <strong>DROXIA (hydroxyurea), ENDARI (L-glutamine oral powder), ADAKVEO (crizanlizumab-tmca), and OXBRYTA (voxelotor)<\/strong>.&nbsp;<\/p>\n\n\n\n<p>Enhancing care and outcomes for <a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-6mm-epidemiology-forecast\">individuals with sickle cell disease<\/a> requires a multidisciplinary approach. This includes access to comprehensive healthcare services, genetic counseling, early detection, and effective management of complications. Patient education and support programs play a vital role in empowering individuals to manage their condition and improve their quality of life.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Ongoing research and development efforts aim to discover new treatments and potential cures for sickle cell disease. Gene therapy and gene editing techniques show promise in addressing the underlying genetic mutation responsible for the condition. Clinical trials are actively evaluating the safety and efficacy of these innovative therapies, offering hope for a future where Sickle Cell Disease is either cured or effectively managed.<\/p>\n\n\n\n<p>The disease poses a significant burden due to its life-threatening nature and the lack of effective treatment options. Until the last decade, hydroxyurea was the only available management option. However, despite its long presence in the market, challenges persist with low adherence to treatment and high discontinuation rates.<\/p>\n\n\n\n<p>Delays in diagnosis, serious complications of sickle cell disease, economic burden, and lack of proper understanding of the disease will be going to hit the sickle cell disease market. As per DelveInsight analysis, in 2023, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-6mm-market\">total market size of sickle cell disease<\/a> was approximately <strong>USD 650 million<\/strong>, which is expected to increase by 2034 during the study period (2020\u20132034) in the 6MM.<\/p>\n\n\n\n<p>In conclusion, sickle cell disease is a complex genetic blood disorder characterized by abnormal hemoglobin, leading to complications and reduced life expectancy. However, advancements in treatment approaches and ongoing research efforts offer hope for improved management and potential cures. Enhancing healthcare services, raising awareness, and supporting individuals with sickle cell disease are essential steps toward addressing the challenges associated with this disease in the 6MM.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-6mm-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151923\/Sickle-Cell-Disease-Market-Outlook-and-Assessment-1024x194.png\" alt=\"Sickle Cell Disease Market Outlook and Assessment\" class=\"wp-image-30676\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151923\/Sickle-Cell-Disease-Market-Outlook-and-Assessment-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151923\/Sickle-Cell-Disease-Market-Outlook-and-Assessment-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151923\/Sickle-Cell-Disease-Market-Outlook-and-Assessment-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151923\/Sickle-Cell-Disease-Market-Outlook-and-Assessment-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151923\/Sickle-Cell-Disease-Market-Outlook-and-Assessment-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151923\/Sickle-Cell-Disease-Market-Outlook-and-Assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Sickle cell disease is a hereditary blood disorder marked by abnormal hemoglobin, which leads to the deformation of red blood cells into a sickle shape. It is a major global health issue, especially common in individuals of African, Middle Eastern, Mediterranean, and South Asian descent. Based on DelveInsight&#8217;s assessment in 2023, the total prevalent cases [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30673,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[258,536,7102,17843,7101,17844],"industry":[17225],"therapeutic_areas":[17233],"class_list":["post-30668","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-gene-therapy","tag-sickle-cell-disease","tag-sickle-cell-disease-market","tag-sickle-cell-disease-patients","tag-sickle-cell-disease-therapy","tag-sickle-cell-disease-treatment-approaches","industry-pharmaceutical","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Role of Gene Therapy and Editing in Sickle Cell Disease Treatment<\/title>\n<meta name=\"description\" content=\"Gene therapy and gene editing techniques hold promise in correcting underlying genetic mutation responsible for sickle cell disease treatment\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Role of Gene Therapy and Editing in Sickle Cell Disease Treatment\" \/>\n<meta property=\"og:description\" content=\"Gene therapy and gene editing techniques hold promise in correcting underlying genetic mutation responsible for sickle cell disease treatment\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-27T11:50:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151741\/gene-therapy-for-sickle-cell-disease-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Role of Gene Therapy and Editing in Sickle Cell Disease Treatment","description":"Gene therapy and gene editing techniques hold promise in correcting underlying genetic mutation responsible for sickle cell disease treatment","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment","og_locale":"en_US","og_type":"article","og_title":"Role of Gene Therapy and Editing in Sickle Cell Disease Treatment","og_description":"Gene therapy and gene editing techniques hold promise in correcting underlying genetic mutation responsible for sickle cell disease treatment","og_url":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-12-27T11:50:00+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151741\/gene-therapy-for-sickle-cell-disease-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment","url":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment","name":"Role of Gene Therapy and Editing in Sickle Cell Disease Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151741\/gene-therapy-for-sickle-cell-disease-treatment.png","datePublished":"2024-12-27T11:50:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Gene therapy and gene editing techniques hold promise in correcting underlying genetic mutation responsible for sickle cell disease treatment","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-sickle-cell-disease-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151741\/gene-therapy-for-sickle-cell-disease-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151741\/gene-therapy-for-sickle-cell-disease-treatment.png","width":772,"height":482,"caption":"gene-therapy-for-sickle-cell-disease-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/24151741\/gene-therapy-for-sickle-cell-disease-treatment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">sickle cell disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">sickle cell disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sickle Cell Disease Patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">sickle cell disease therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sickle Cell Disease Treatment Approaches<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">sickle cell disease<\/span>","<span class=\"advgb-post-tax-term\">sickle cell disease market<\/span>","<span class=\"advgb-post-tax-term\">Sickle Cell Disease Patients<\/span>","<span class=\"advgb-post-tax-term\">sickle cell disease therapy<\/span>","<span class=\"advgb-post-tax-term\">Sickle Cell Disease Treatment Approaches<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Dec 27, 2024","modified":"Updated on Dec 24, 2024"},"absolute_dates_time":{"created":"Posted on Dec 27, 2024 5:20 pm","modified":"Updated on Dec 24, 2024 3:21 pm"},"featured_img_caption":"gene-therapy-for-sickle-cell-disease-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30668"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30668\/revisions"}],"predecessor-version":[{"id":30678,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30668\/revisions\/30678"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30673"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30668"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30668"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}